Dual effects of androgens on mammary gland;Effet dual des androgènes sur la glande mammaire

Bulletin du Cancer

Volumn 95, Issue 5, 2008, Pages 495-502

  Brettes, Jean Philippe ^a   Mathelin, Carole ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Androgen; Aromatase; Breast cancer; Progesterone; Receptor

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; ESTROGEN RECEPTOR; GESTAGEN;

AGING; ANDROGEN BLOOD LEVEL; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; DRUG EFFECT; ENZYME MECHANISM; ESTROGEN BLOOD LEVEL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; MAMMARY GLAND; REVIEW;

AGE FACTORS; ANDROGEN ANTAGONISTS; ANDROGENS; BREAST NEOPLASMS; CELL PROLIFERATION; DIHYDROTESTOSTERONE; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; NEOPLASMS, HORMONE-DEPENDENT; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 45949103527     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0631     Document Type: Review

References (61)

1. Beatson G. Of the treatment of inoperable cases of carcinoma of the mamma : suggestions for a new method of treatment with illustrative cases. Lancet 1896 ; 2 : 104-7.
2. Bowers WF, Nicholas TH, Kovaric JJ. Bilateral adrenalectomy for advanced breast cancer ; a report of eleven cases. Cancer 1956 ; 9 : 277-80.
3. Cade S. The role of adrenalectomy in cancer of the breast. Cancer 1957 ; 10 : 777-88.
4. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women : the Rancho Bernardo Study. J Clin Endocrinol Metab 2000 ; 85 : 645-51.
5. De Cremoux P, Dieras V, Poupon MF, Magdelenat H, Sigal-Zafrani B, Fourquet A, et al. Tamoxifen and aromatase inhibitors in the treatment of breasr cancer in menopausal women : pharmacological and clinical aspects. Bull Cancer 2004 ; 91 : 917-27.
6. Younus J, Vandenberg TA. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer. Bull Cancer 2005 ; 92 : E39-E44.
7. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003 ; 120 : 725-31.
8. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, et al. Androgen receptors frequently are expressed in breast carcinomas : potential relevance to new therapeutic strategies. Cancer 2003 ; 98 : 703-11.
9. Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001 ; 86 : 5060-6.
10. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists : distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 1999 ; 13 : 440-54.
11. Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues : intracrinology. Front Neuroendocrinol 2001 ; 22 : 185-212.
12. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, et al. Endocrine and intracrine sources of androgens in women : inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003 ; 24 : 152-82.
13. Chang C, Kokontis J. Identification of a new member of the steroid receptor super-family by cloning and sequence analysis. Biochem Biophys Res Commun 1988 ; 155 : 971-7.
14. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988 ; 240 : 327-30.
15. Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam Horm 1994 ; 49 : 383-432.
16. Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol 2001 ; 106 (2 Suppl 1) : 111-25.
17. Schmitt M, Klinga K, Schnarr B, Morfin R, Mayer D. Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol. Mol Cell Endocrinol 2001 ; 173 : 1-13.
18. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002 ; 16 : 113-20.
19. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, et al. 5alpha-reductases in human breast carcinoma : possible modulator of in situ androgenic actions. J Clin Endocrinol Metab 2001 ; 86 : 2250-7.
20. Janssen PJ, Brinkmann AO, Boersma WJ, Van der Kwast TH. Immunohistochemical detection of the androgen receptor with monoclonal antibody F39-4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histochem Cytochem 1994 ; 42 : 1169-75.
21. Zhuang YH, Saaristo R, Ylikomi T. An in vitro long-term culture model for normal human mammary gland : expression and regulation of steroid receptors. Cell Tissue Res 2003 ; 311 : 217-26.
22. Kandouz M, Lombet A, Perrot JY, Jacob D, Carvajal S, Kazem A, et al. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol 1999 ; 69 : 463-71.
23. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000 ; 60 : 5946-9.
24. Riva C, Dainese E, Caprara G, Rocca PC, Massarelli G, Tot T, et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 2005 ; 447 : 695-700.
25. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 1984 ; 54 : 2436-40.
26. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996 ; 32A : 1560-5.
27. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007 ; 109 : 25-32.
28. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 2000 ; 167 : 139-50.
29. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000 ; 14 : 1725-30.
30. Hirose K, Matsuo K, Toyama T, Iwata H, Hamajima N, Tajima K. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers Prev 2004 ; 13 : 1407-11.
31. Dimitrakakis C, Zhou J, Bondy CA. Androgens and mammary growth and neoplasia. Fertil Steril 2002 ; 77 (Suppl 4) : S26-S33.
32. Dorgan JF, Stanczyk FZ, Longcope C, Stephenson Jr. HE, Chang L, Miller R, et al. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 bera, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1997 ; 6 : 177-81.
33. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002 ; 80 : 175-89.
34. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999 ; 130 : 270-7.
35. Zheng W, Gao YT, Shu XO, Wen W, Cai Q, Dai Q, et al. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004 ; 13 : 709-14.
36. Baghaei F, Rosmond R, Westberg L, Hellstrand M, Eriksson E, Holm G, et al. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes Res 2003 ; 11 : 578-85.
37. Dialyna I, Tzanakakis G, Dolapsakis G, Tsatsakis A. A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides. Toxicol Lett 2004 ; 151 : 267-71.
38. Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000 ; 87 : 204-10.
39. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999 ; 8 : 843-54.
40. Cox DG, Blanche H, Pearce CL, Calle EE, Colditz GA, Pike MC, et al. A comprehensive analysis of the androgen receptor gene and risk of breast cancer : results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res 2006 ; 8 : R54.
41. Liede A, Zhang W, De Leon Matsuda ML, Tan A, Narod SA. Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines. Cancer Epidemiol Biomarkers Prev 2003 ; 12 : 848-52.
42. Lillie EO, Bernstein L, Ingles SA, Gauderman WJ, Rivas GE, Gagalang V, et al. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res 2004 ; 64 : 1237-41.
43. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999 ; 64 : 1371-7.
44. Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA. Androgen receptor (CAG) n and (GGC) n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 2003 ; 12 : 127-35.
45. Kristiansen M, Langerod A, Knudsen GP, Weber BL, Borresen-Dale AL, Orstavik KH. High frequency of skewed X inactivation in young breast cancer patients. J Med Genet 2002 ; 39 : 30-3.
46. De Abreu FB, Pirolo LJ, Canevari Rde A, Rosa FE, Moraes Neto FA, Caldeira JR, et al. Shorter CAG repeat in the AR gene is associated with atypical hyperplasia and breast carcinoma. Anticancer Res 2007 ; 27 : 1199-205.
47. Zhang W, Yu YY. Polymorphisms of short tandem repeat of genes and breast cancer susceptibility. Eur J Surg Oncol 2007 ; 33 : 529-34.
48. Tran N, Bharaj BS, Diamandis EP, Smith M, Li BD, Yu H. Short tandem repeat polymorphism and cancer risk : influence of laboratory analysis on epidemiologic findings. Cancer Epidemiol Biomarkers Prev 2004 ; 13 : 2133-40.
49. Washbrook E. Risk factors and epidemiology of breast cancer. Women's Health Medicine 2006 ; 3 : 1-7.
50. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer : the predictive value of androgen receptor expression. J Clin Oncol 1995 ; 13 : 1572-7.
51. Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res 2005 ; 65 : 8487-96.
52. Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB. The progestational and androgenic properties of medroxyprogesterone acetate : gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res 2005 ; 7 : R1036-R1050.
53. Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J 2007 ; 21 : 2285-93.
54. Rody A, Diallo R, Poremba C, Wuelfing P, Kissler S, Solbach C, et al. Androgen receptor expression in ductal carcinoma in situ of the breast : not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor. Appl Immunohistochem Mol Morphol 2005 ; 13 : 25-9.
55. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006 ; 25 : 3994-4008.
56. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005 ; 24 : 4660-71.
57. Xie B, Tsao SW, Wong YC. Sex hormone-induced mammary carcinogenesis in female noble rats : the role of androgens. Carcinogenesis 1999 ; 20 : 1597-606.
58. Boccuzzi G, Tamagno E, Brignardello E, Di Monaco M, Aragno M, Danni O. Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J Cancer Res Clin Oncol 1995 ; 121 : 150-4.
59. http://clinicaltrials.gov/ct/show/NCT00468715.
60. Moe RE, Anderson BO. Androgens and androgen receptors : a clinically neglected sector in breast cancer biology. J Surg Oncol 2007 ; 95 : 437-9.
61. Berrino F, Pasanisi P, Bellati C, Venturelli E, Krogh V, Mastroianni A, et al. Serum testosterone levels and breast cancer recurrence. Int J Cancer 2005 ; 113 : 499-502.